Retatrutide (LY3437943) is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, currently without marketing authorisation from the MHRA or EMA
Care begins with a thorough consultation, a detailed understanding of each patients health history, and a discussion of goals
The key takeaway is that GHK-CU produces measurable, documented improvements when used consistently at appropriate doses
Sperm DNA fragmentation is a clinically validated predictor of pregnancy loss 51 , and its reduction from 8.3% (control) to 5.0% at 100 g/mL, approaching the 5% AI semen quality threshold, likely contributed to improved embryo survival following cervical insemination
GLP-1 receptor agonists like semaglutide have transformed weight management for millions of people worldwide
doi:10.1016/j.molmet.2019.09.010 Mller TD, Finan B, Bloom SR, et al